Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
22541
Shown on this page
12
Current sort
Recently updated
Location scope
Houston, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Houston, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 973–984 of 22,541 matching trials in Houston, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Houston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
Interventions
TRI-611
Drug
Lead sponsor
TRIANA Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 10 more
Conditions
Multi Center, Phase 2, Golcadomide, Glofitamab, Polauzumab, Vedotin, G2p, B Cell Lymphoma
Interventions
golcadomide, Obinutuzumab, Polatuzumab, Glofitamab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neoplasms
Interventions
Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
63
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 38 more
Active, not recruiting Phase 3 Interventional Results available

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197
Conditions
mCRPC
Interventions
Talazoparib with enzalutamide, Placebo with enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
132
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 93 more
Conditions
HIV Infections
Interventions
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more
Conditions
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more
Conditions
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Interventions
CTX131
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Conditions
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Interventions
Pumitamig, Folfox, Capox, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 29 more
Conditions
Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Phase 3 Interventional Results available

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

NCT04526665
Conditions
Primary Biliary Cirrhosis
Interventions
Elafibranor 80mg, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
46
States / cities
Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more
Conditions
Lung Biopsy, Lung Cancer, Lung Cancer (Diagnosis)
Interventions
Not listed
Lead sponsor
Invenio Imaging Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
San Diego, California • Jacksonville, Florida • Grand Rapids, Michigan + 4 more
Conditions
Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer
Interventions
P-MUC1C-ALLO1 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2039
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 11 more